Taysha Gene Therapies (NASDAQ:TSHA) Receives “Buy” Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note published on Tuesday, Benzinga reports. They currently have a $7.00 price target on the stock.

Other analysts also recently issued research reports about the stock. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an overweight rating and a $9.00 price objective for the company. Canaccord Genuity Group reaffirmed a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Needham & Company LLC reissued a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Monday. Cantor Fitzgerald reissued an overweight rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, May 28th. Finally, JMP Securities restated a market outperform rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of Buy and an average price target of $7.00.

Taysha Gene Therapies Stock Down 26.3 %

Shares of TSHA opened at $2.97 on Tuesday. Taysha Gene Therapies has a 52 week low of $0.50 and a 52 week high of $4.32. The firm has a market cap of $555.45 million, a P/E ratio of -6.06 and a beta of 0.49. The firm’s 50-day simple moving average is $3.00 and its 200 day simple moving average is $2.38. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the previous year, the firm posted ($0.28) EPS. On average, analysts forecast that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of the stock. FMR LLC increased its stake in shares of Taysha Gene Therapies by 2,035.0% in the third quarter. FMR LLC now owns 24,527,801 shares of the company’s stock worth $77,508,000 after buying an additional 23,378,974 shares during the period. RA Capital Management L.P. bought a new position in Taysha Gene Therapies in the 3rd quarter worth about $58,373,000. RTW Investments LP bought a new position in Taysha Gene Therapies during the 3rd quarter valued at about $53,382,000. Avoro Capital Advisors LLC lifted its stake in Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after acquiring an additional 14,294,445 shares during the period. Finally, Acuta Capital Partners LLC purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter valued at about $12,096,000. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.